Psoriatic arthritis
Conditions
Interventions
Experimental group:The pertuzumab 240 mg is administered by subcutaneous injection at weeks 0, 2, and 4, followed by dosing every 4 weeks, with the last injection at week 24.
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Study participants voluntarily signed the informed consent form prior to the initiation of the study. 2. At the time of signing the informed consent, participants were aged >=18 and=3 tender joints and >=3 swollen joints). Prior to screening, participants should have been treated with non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks, with inadequate symptom control or intolerance to NSAIDs.
Exclusion criteria
Exclusion criteria: 1. Presence of any of the following medical histories or comorbid conditions: drug-induced psoriasis; other active inflammatory or autoimmune diseases; history of organ transplantation; history of lymphoproliferative disorders; severe infections; malignant tumors; psychiatric disorders, etc. 2. Prior use of any biological agents other than anti-TNF drugs, or prior use of =3 types of anti-TNF drugs. 3. Allergy to any component or excipient of the investigational drug. 4. Pregnancy or lactation in female participants; history of alcohol abuse or illicit drug use, etc. 5. Any other conditions considered by the investigator as inappropriate for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ACR20; | — |
Countries
China
Contacts
Public ContactSun Qing
Qilu Hospital of Shandong University
Outcome results
None listed